Replimune Group Receives FDA Approval; Mestag Therapeutics Appoints New Board Members
1 report, 1 independent
Updated Tue 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Replimune Group received accelerated approval from the FDA. Separately, Mestag Therapeutics appointed Philip Astley-Sparke and Victor Sandor to its Board of Directors. Mestag Therapeutics is advancing the Phase I STARLYS trial for MST-0312, a targeted lymphotoxin-beta agonist bispecific antibody for advanced solid tumors.
From manilatimes.net
Why it matters
The FDA approval for Replimune Group marks a regulatory milestone for the company. Mestag Therapeutics' appointments bring specialized clinical and regulatory expertise to the company as it evaluates its drug candidate, MST-0312.
From manilatimes.net
Who's involved
- FDARegulatory agency that granted accelerated approval to Replimune Group
- AstraZenecaPharmaceutical company where Victor Sandor previously led oncology clinical development programs
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
AstraZeneca
British-Swedish pharmaceutical company
- FDA